Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform
2017-07-12 14:10 ET - News Release
GAITHERSBURG, Maryland, July 12, 2017 /PRNewswire/ --
Genetic Health Solution platform helps chronic disease patient management
Patient-centric biomarker-based wellness programs designed to improve outcomes
Avant Diagnostics, Inc. ("Avant"
(OTC: AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, acquired an exclusive option to license the patient-delivery technology platform from Genetic Health Solution ("GHS", website: http://www.genetichealthsolution.com). GHS is a functional medicine practice that specializes in the aggregation and analysis of advanced biomarker testing data to provide tailored product recommendations for health optimization.
As part of the agreement, the management teams of both companies will endeavor to build an oncology-focused personalized health optimization program to improve health outcomes for patients based upon oncology drugs' side effect profiles combined with advanced blood biomarker monitoring. Taken together, the companies believe they can establish a best-in-class personalized cancer patient management program tailored to allow physicians and patients to proactively mitigate potential negative drug side effects, as well as boost overall health.
Concurrent with this announcement, the Company is evaluating an initial Theralink® product launch in breast cancer that will focus on a specific treatment paradigm where our proprietary assay can immediately impact a large population of patients who may be prescribed ineffective treatments due to the insufficient biomarker testing methods currently available. The patient population of interest, with the additional Theralink information, would receive a different prescription therapy that is likely to lead to a well-defined improvement in outcomes based upon the published literature.
2017-07-12 14:10 ET - News Release
GAITHERSBURG, Maryland, July 12, 2017 /PRNewswire/ --
Genetic Health Solution platform helps chronic disease patient management
Patient-centric biomarker-based wellness programs designed to improve outcomes
Avant Diagnostics, Inc. ("Avant"
(OTC: AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, acquired an exclusive option to license the patient-delivery technology platform from Genetic Health Solution ("GHS", website: http://www.genetichealthsolution.com). GHS is a functional medicine practice that specializes in the aggregation and analysis of advanced biomarker testing data to provide tailored product recommendations for health optimization. As part of the agreement, the management teams of both companies will endeavor to build an oncology-focused personalized health optimization program to improve health outcomes for patients based upon oncology drugs' side effect profiles combined with advanced blood biomarker monitoring. Taken together, the companies believe they can establish a best-in-class personalized cancer patient management program tailored to allow physicians and patients to proactively mitigate potential negative drug side effects, as well as boost overall health.
Concurrent with this announcement, the Company is evaluating an initial Theralink® product launch in breast cancer that will focus on a specific treatment paradigm where our proprietary assay can immediately impact a large population of patients who may be prescribed ineffective treatments due to the insufficient biomarker testing methods currently available. The patient population of interest, with the additional Theralink information, would receive a different prescription therapy that is likely to lead to a well-defined improvement in outcomes based upon the published literature.
5
